Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is reporting third quarter earnings results on Thursday 5th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 1.71 per share.
For the full year, analysts predict revenues of $ 570.39 million, while looking forward to loss of $ 5.98 per share.
Previous Quarter Performance
Sarepta Therapeutics, Inc. reported loss for the second quarter of $ 1.51 per share, from the revenue of $ 137.36 million. The consensus estimates are loss of $ 1.72 per share from $ 118.78 million in revenue. The bottom line results beat street analysts by $ 0.21 or 12.21 percent, at the same time, top line results outshined analysts by $ 18.58 million or 15.64 percent.
Stock Performance
Shares of Sarepta Therapeutics, Inc. traded up $ 10.56 or 7.47 percent on Wednesday, reaching $ 151.90 with volume of 910.90 thousand shares. Sarepta Therapeutics, Inc. has traded high as $ 153.95 and has cracked $ 143.06 on the downward trend
The closing price of $ 151.90, representing a 81.07 % increase from the 52 week low of $ 78.06 and a 19.23 % decrease over the 52 week high of $ 175.00.
The company has a market capital of $ 11.92 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 15th September 2020, maintained by Citigroup at Buy rating, with $ 190.00 target price.
Conference Call
Sarepta Therapeutics, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.sarepta.com
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD).
